Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
shaohong, dong
NCT04759534: Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia	Active, not recruiting	3	20	RoW	protein convertase subtilisin/kexin type 9 inhibitor	Shenzhen People's Hospital, Innovent Biopharmaceutical Co., Ltd.	Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9	10/21	11/21
LQY-PCSK9-Homozygous, NCT04948008: Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia	Recruiting	2b/3	8	RoW	IBI306	Shenzhen People's Hospital	Familial Hypercholesterolemia - Homozygous, Lipid Metabolism Disorders, Proprotein Convertase Subtilisin/Kexin 9	07/20	12/22
guang, huo
LQY-PCSK9-Homozygous, NCT04948008: Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia	Recruiting	2b/3	8	RoW	IBI306	Shenzhen People's Hospital	Familial Hypercholesterolemia - Homozygous, Lipid Metabolism Disorders, Proprotein Convertase Subtilisin/Kexin 9	07/20	12/22